In mice with obesity and T2DM, the diet-induced activation of the NLRP3 inflammasome in the kidney and liver was blunted by empagliflozin treatment, shown by the reduction in caspase-1 activation and the production of IL-1β, along with lipid accumulation, an effect not observed in the heart despite the efficient reduction of cardiac lipid accumulation [234]. Here, NLRP3 is linked to type 2 diabetes mellitus.